THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT – PR Newswire

Leave a Comment / Pharma and Biotech / By

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE pact TO BE bought BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT  PR Newswire

Source: news.google.com

Related Posts

Leave a Comment

Your email address will not be published. Required fields are marked *